MBOT Quote, Financials, Valuation and Earnings

Accuray, Inc. has a net margin of -- compared to Microbot Medical, Inc.'s net margin of -13.47%. Microbot Medical, Inc.'s return on equity of -45.11% beat Accuray, Inc.'s return on equity of -60.6%.

Microbot Medical, Inc. has a consensus price target of $7.50, signalling upside risk potential of 202.42%. On the other hand Accuray, Inc. has an analysts' consensus of $2.53 which suggests that it could grow by 357.84%. Given that Accuray, Inc. has higher upside potential than Microbot Medical, Inc., analysts believe Accuray, Inc. is more attractive than Microbot Medical, Inc..

Microbot Medical, Inc. has a beta of 1.225, which suggesting that the stock is 22.477% more volatile than S&P 500. In comparison Accuray, Inc. has a beta of 1.192, suggesting its more volatile than the S&P 500 by 19.162%.

Microbot Medical, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Accuray, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Microbot Medical, Inc. pays -- of its earnings as a dividend. Accuray, Inc. pays out -- of its earnings as a dividend.

Microbot Medical, Inc. quarterly revenues are --, which are smaller than Accuray, Inc. quarterly revenues of $102.2M. Microbot Medical, Inc.'s net income of -$3.6M is higher than Accuray, Inc.'s net income of -$13.8M. Notably, Microbot Medical, Inc.'s price-to-earnings ratio is -- while Accuray, Inc.'s PE ratio is 149.00x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Microbot Medical, Inc. is -- versus 0.14x for Accuray, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Alphatec Holdings, Inc. has a net margin of -- compared to Microbot Medical, Inc.'s net margin of -10.21%. Microbot Medical, Inc.'s return on equity of -45.11% beat Alphatec Holdings, Inc.'s return on equity of -1092.5%.

Microbot Medical, Inc. has a consensus price target of $7.50, signalling upside risk potential of 202.42%. On the other hand Alphatec Holdings, Inc. has an analysts' consensus of $24.62 which suggests that it could grow by 82.74%. Given that Microbot Medical, Inc. has higher upside potential than Alphatec Holdings, Inc., analysts believe Microbot Medical, Inc. is more attractive than Alphatec Holdings, Inc..

Microbot Medical, Inc. has a beta of 1.225, which suggesting that the stock is 22.477% more volatile than S&P 500. In comparison Alphatec Holdings, Inc. has a beta of 1.020, suggesting its more volatile than the S&P 500 by 1.994%.

Microbot Medical, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Alphatec Holdings, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Microbot Medical, Inc. pays -- of its earnings as a dividend. Alphatec Holdings, Inc. pays out -- of its earnings as a dividend.

Microbot Medical, Inc. quarterly revenues are --, which are smaller than Alphatec Holdings, Inc. quarterly revenues of $212.9M. Microbot Medical, Inc.'s net income of -$3.6M is higher than Alphatec Holdings, Inc.'s net income of -$21.7M. Notably, Microbot Medical, Inc.'s price-to-earnings ratio is -- while Alphatec Holdings, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Microbot Medical, Inc. is -- versus 2.64x for Alphatec Holdings, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Boston Scientific Corp. has a net margin of -- compared to Microbot Medical, Inc.'s net margin of 12.68%. Microbot Medical, Inc.'s return on equity of -45.11% beat Boston Scientific Corp.'s return on equity of 12.55%.

Microbot Medical, Inc. has a consensus price target of $7.50, signalling upside risk potential of 202.42%. On the other hand Boston Scientific Corp. has an analysts' consensus of $104.75 which suggests that it could grow by 37.43%. Given that Microbot Medical, Inc. has higher upside potential than Boston Scientific Corp., analysts believe Microbot Medical, Inc. is more attractive than Boston Scientific Corp..

Microbot Medical, Inc. has a beta of 1.225, which suggesting that the stock is 22.477% more volatile than S&P 500. In comparison Boston Scientific Corp. has a beta of 0.688, suggesting its less volatile than the S&P 500 by 31.155%.

Microbot Medical, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Boston Scientific Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Microbot Medical, Inc. pays -- of its earnings as a dividend. Boston Scientific Corp. pays out -- of its earnings as a dividend.

Microbot Medical, Inc. quarterly revenues are --, which are smaller than Boston Scientific Corp. quarterly revenues of $5.3B. Microbot Medical, Inc.'s net income of -$3.6M is lower than Boston Scientific Corp.'s net income of $670M. Notably, Microbot Medical, Inc.'s price-to-earnings ratio is -- while Boston Scientific Corp.'s PE ratio is 39.31x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Microbot Medical, Inc. is -- versus 5.67x for Boston Scientific Corp.. Usually stocks with elevated PS ratios are considered overvalued.

Plus Therapeutics, Inc. has a net margin of -- compared to Microbot Medical, Inc.'s net margin of -316.61%. Microbot Medical, Inc.'s return on equity of -45.11% beat Plus Therapeutics, Inc.'s return on equity of --.

Microbot Medical, Inc. has a consensus price target of $7.50, signalling upside risk potential of 202.42%. On the other hand Plus Therapeutics, Inc. has an analysts' consensus of $5.50 which suggests that it could grow by 1735.78%. Given that Plus Therapeutics, Inc. has higher upside potential than Microbot Medical, Inc., analysts believe Plus Therapeutics, Inc. is more attractive than Microbot Medical, Inc..

Microbot Medical, Inc. has a beta of 1.225, which suggesting that the stock is 22.477% more volatile than S&P 500. In comparison Plus Therapeutics, Inc. has a beta of 0.788, suggesting its less volatile than the S&P 500 by 21.173%.

Microbot Medical, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Plus Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Microbot Medical, Inc. pays -- of its earnings as a dividend. Plus Therapeutics, Inc. pays out -- of its earnings as a dividend.

Microbot Medical, Inc. quarterly revenues are --, which are smaller than Plus Therapeutics, Inc. quarterly revenues of $1.4M. Microbot Medical, Inc.'s net income of -$3.6M is higher than Plus Therapeutics, Inc.'s net income of -$4.4M. Notably, Microbot Medical, Inc.'s price-to-earnings ratio is -- while Plus Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Microbot Medical, Inc. is -- versus 4.80x for Plus Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.